Mississauga, Canada
CanVeer Biopharma Inc. (the “Company” or “CanVeer”), a biopharma company advancing innovative therapeutics for severe neonatal conditions, is pleased to announce that it has received approval from Intellectual Property Ontario (IPON) for the funding of its first Statement of Work (SOW) under the IPON funding program, supporting the advancement of the Company’s intellectual property (IP) strategy.
The approved funding will support CanVeer’s collaboration with SMART & BIGGAR LLP, the Company’s IP legal counsel, to further develop and strengthen its IP portfolio. This work will include expanding patent claims related to the formulation and mode of delivery of AlveoShield™, the Company’s lead investigational therapeutic candidate designed to potentially prevent and treat bronchopulmonary dysplasia (BPD) in preterm neonates.
As the Company previously announced on January 28, 2026, CanVeer was accepted into the highly competitive IPON program and is eligible to receive up to CAD $300,000 in non-dilutive funding (on an 80% cost-sharing basis) to support IP development and commercialization strategy.
IPON is a provincial initiative that supports Ontario companies in building and protecting globally competitive intellectual property. Participation in the program reflects external validation of CanVeer’s technology and strategic direction.
CanVeer currently holds a United States provisional patent governing its therapeutic platform for respiratory conditions, including its lead program AlveoShield. The Company plans to pursue expanded patent protection through national and international filings, including a PCT application targeted for Q2 2026.
Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting premature infants born with underdeveloped lungs who require oxygen therapy at birth. The necessary life-saving oxygen therapy often contributes to lung injury and the development of BPD. Children who develop BPD face lifelong respiratory complications and higher rate of morbidity. In North America, approximately 13–15% of newborns are born preterm, with approximately 40-60% requiring respiratory support at birth, placing an estimated 150,000–180,000 infants annually at risk of developing BPD. To date, there is no approved therapy for BPD in the clinic.
AlveoShield™, CanVeer’s proprietary investigational therapeutic candidate, is the first in kind disease modifying program, designed to target underlying biological pathways associated with lung injury, with the goal of preventing disease development rather than managing symptoms. The program is supported by a growing body of translational research and pre-clinical efficacy evidence including studies in human neonatal lung tissue, in vitro systems, and juvenile animal models.
“Advancing our intellectual property strategy and establishing long-term market exclusivity are key priorities for CanVeer,” said Sherif Louis, Chief Executive Officer of CanVeer. “Our collaboration with SMART & BIGGAR enables us to strategically expand our patent protection across therapeutic use, formulation, and delivery approaches as we prepare for clinical development.”
About CanVeer Biopharma Inc.
CanVeer Biopharma is a privately owned pre-clinical biopharmaceutical company advancing innovative therapeutics for chronic diseases with high unmet medical needs. The Company’s lead program, AlveoShield™, is being developed as a potential therapy for bronchopulmonary dysplasia (BPD), a severe chronic respiratory condition affecting preterm infants who require assisted ventilation at birth. Currently, there are no approved disease-modifying therapies for BPD. AlveoShield™ is designed to target biological pathways underlying lung injury to support normal lung development.
For more information, please visit www.canveer.com.
For further information, please contact:
Sherif Louis
[email protected]
6472936555
http://www.canveer.com/
Last modified: March 25, 2026
